2022 its PE may be less than 10

CrisisInvesting

Pfizer (PFE) First-Quarter 2022 Revenues of $25.7 Billion, Reflecting 82% Operational Growth; Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Increased 2% Operationally

First-Quarter 2022 Reported Diluted EPS(2) of $1.37 and Adjusted Diluted EPS(3) of $1.62

Both Reported(2) and Adjusted(3) Diluted EPS Include a $0.05 Negative Impact for Acquired In-Process R&D Expenses(4), Which Prior to First-Quarter 2022 Had Largely Been Excluded From Adjusted(3) Results

Reaffirms Full-Year 2022 Financial Guidance(4) for Revenues of $98.0 to $102.0 Billion, Which Includes Operational Increases Offset by Approximately $2 Billion of Negative Foreign Exchange Impacts

Reaffirms 2022 Revenue Guidance for Comirnaty(1) of Approximately $32 Billion, Despite a ~$1 Billion Unfavorable Impact from Foreign Exchange

Reaffirms 2022 Revenue Guidance for Paxlovid of Approximately $22 Billion, Despite a ~$0.5 Billion Unfavorable Impact from Foreign Exchange

Full-Year 2022 Financial Guidance(4) for Adjusted Diluted EPS(3) Revised to a Range of $6.25 to $6.45 Solely to Reflect an $0.11 Negative Impact for an Accounting Policy Change to Include All Acquired In-Process R&D Expenses(4) in Adjusted(3) Results

Operational Increases Offset the Additional Negative Impact of $0.11 Due to Unfavorable Foreign Exchange

Provides Updates and New Data for Select Clinical Programs Related to COVID-19, Inflammation & Immunology, Vaccines, Oncology and Rare Disease on Analyst Conference Call

NEW YORK, May 03, 2022--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance, including its guidance for Comirnaty(1), the Pfizer-BioNTech SE (BioNTech) COVID-19 vaccine, and for Paxlovid, its oral COVID-19 treatment, despite unfavorable impacts from foreign exchange.